香港股市 已收市

Zydus Lifesciences Limited (ZYDUSLIFE.NS)

NSE - NSE 即時價格。貨幣為 INR。
加入追蹤清單
1,007.35+7.65 (+0.77%)
收市:03:29PM IST

Zydus Lifesciences Limited

Zydus Corporate Park
Scheme No. 63 Survey No. 536, Khoraj (Gandhinagar) Nr. Vaishnodevi Circle, S. G. Highway
Ahmedabad 382481
India
91 79 7180 0000
https://www.zyduslife.com

版塊Healthcare
行業Drug Manufacturers - Specialty & Generic
全職員工23,026

高階主管

名稱頭銜支付行使價出生年份
Dr. Sharvil Pankajbhai PatelMD & Executive Director262.5M1979
Dr. Ganesh Narayan NayakCOO & Executive Director120M1955
Mr. Punit PatelPresident & CEO of America
Mr. Nitinkumar Dalsukhray ParekhChief Financial Officer54.31M
Mr. Arvind BothraHead of Investor Relations
Mr. Dhaval Narendra SoniCompany Secretary & Compliance Officer2.09M
截止 2023年12月31日為止計算的金額,現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 INR。

描述

Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through Pharmaceuticals and Consumer Products segments. It offers finished dosage human formulations comprising generics, branded generics, and specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients; consumer wellness products; and products in the therapeutic areas of pain management, neurology, metabolic disorder, and liver diseases. The company offers the products under the Everyuth and Nutralite, Complan, Glucon D, and Nycil brands. In addition, the company offers a pipeline of biological products in the areas of oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology, and infectious illnesses. Further, it engages in the investment, animal health and veterinary, pharmacy retail, and manpower supply and administration activities. The company was formerly known as Cadila Healthcare Limited and changed its name to Zydus Lifesciences Limited in February 2022. Zydus Lifesciences Limited was founded in 1952 and is headquartered in Ahmedabad, India.

公司管治

截至 2024年3月1日 止,Zydus Lifesciences Limited 的 ISS 管治質素評分為 5。 Pillar 分數正在審核中:8;董事會:4;股東權利:9;現金賠償:5。

企業管治評分的資料提供: Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險,而 10 分表示較高的管治風險。